This is a SEIS/EIS qualified investment, our focus is on supporting pharmaceutical brands through physician and patient engagement. 



Bearing in mind the previously illustrated cost to pharm of non-compliance, our new technology offers an innovative opportunity to improve patient health outcomes through education and support and, as a result, maximise the lifetime value of a brand

The revenue model is based on system set-up fees, followed by SaaS fees for the number of “touches” a pharma company will buy for a patient or physician or both.

As first mover in this exciting space, we have a credible Board and high-level advisors with an impressive track record of disrupting and developing leading service offerings.

Full investor decks are available at your request.